OCRA

One of the most exciting things emerging in the biomedical fields currently is the idea of personalized medicine. Given a patient’s genetic makeup and risk factors, can we optimize treatment regimens to maximize impact on a patient’s prognosis and survival? Some key questions in this area include:

• What is the biological basis for treatment resistance?

• What combinations of mutations are more/less likely to respond to treatment?

• How do various cell models respond to common chemotherapies?

• Does genetic predisposition (e.g. BRCA mutations) play a role in treatment outcomes?

​

​